Xenon Pharmaceuticals Files 8-K Report
Ticker: XENE · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1582313
| Field | Detail |
|---|---|
| Company | Xenon Pharmaceuticals Inc. (XENE) |
| Form Type | 8-K |
| Filed Date | Mar 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: XENE
TL;DR
Xenon Pharma filed an 8-K on March 8th, likely with financial updates. Keep an eye out for details.
AI Summary
On March 8, 2024, Xenon Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing serves as an official notification to the SEC and investors about significant company events or financial updates, ensuring transparency in the market.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate negative or positive financial implications mentioned in the excerpt.
Key Players & Entities
- Xenon Pharmaceuticals Inc. (company) — Registrant
- March 8, 2024 (date) — Date of Report
FAQ
What specific "Other Events" are being reported by Xenon Pharmaceuticals Inc. in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported, only that this item is included in the filing.
Are there any new financial statements or exhibits being filed with this 8-K?
Yes, the filing indicates that "Financial Statements and Exhibits" are part of the report, but the excerpt does not provide details on their content.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is March 8, 2024.
What is Xenon Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 200-3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8.
What is the Commission File Number for Xenon Pharmaceuticals Inc.?
The Commission File Number for Xenon Pharmaceuticals Inc. is 001-36687.
Filing Stats: 463 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-03-08 17:27:10
Filing Documents
- xene-20240308.htm (8-K) — 44KB
- xene-ex99_1.htm (EX-99.1) — 14KB
- img189401473_0.jpg (GRAPHIC) — 5KB
- 0000950170-24-028784.txt ( ) — 184KB
- xene-20240308.xsd (EX-101.SCH) — 30KB
- xene-20240308_htm.xml (XML) — 5KB
01
Item 8.01 Other Events On March 8, 2024, Xenon Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2024 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval in Canada.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission: Exhibit Number Description 99.1 SEDAR+ filing submitted March 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENON PHARMACEUTICALS INC. Date: March 8, 2024 By: /s/ Sherry Aulin Sherry Aulin Chief Financial Officer